Jukka Rissanen
CEO
Pharmatest Services Ltd
Turku, Finland
PhD with 25+ years in drug development for bone diseases, advancing preclinical research and pioneering therapeutic solutions.
My organisation
Pharmatest is a CRO offering predictive preclinical services for diseases with unmet clinical needs. Our focus is on preclinical skeletal and oncology models, with expertise in immuno-oncology and bone metastasis. We specialize in customized model and assay development services and have a strong track record in radiopharmaceutical assessment in preclinical bone metastasis models. Our indication areas also include osteoporosis, osteoarthritis, and rare bone diseases.